Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2.
Anti-S-RBD
BNT162b2
COVID-19
Immunogenicity
Neutralizing antibody
SARS-CoV-2
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
01 Jan 2022
01 Jan 2022
Historique:
received:
12
10
2021
revised:
16
11
2021
accepted:
24
11
2021
pubmed:
30
11
2021
medline:
22
12
2021
entrez:
29
11
2021
Statut:
ppublish
Résumé
Long-term kinetics of anti-RBD IgG and neutralizing antibodies were analyzed in a cohort of COVID-19 naïve health care workers (HCW) undergoing SARS-CoV-2 vaccination. An anti-RBD IgG immunoassay and a surrogate virus neutralization test (sVNT) were performed at different time points up to 6 months after vaccination in 57 HCWs. Values of anti-RBD IgG predicting an high neutralizing bioactivity (>60%) were also calculated. Mean (range) values of anti-RBD IgG were 294.7 (11.6-1554), 2583 (398-8391), 320.4 (42.3-1134) BAU/mL at T1 (21 days after the 1st dose [T0]), T2 (30 days after the 2nd dose) and T3 (+180 days after T0), respectively. Mean (range) percentages of neutralization (NS%) were 24 (0-76), 86 (59-96) and 82 (52-99) at T1, T2 and T3, respectively. Anti-RBD IgG values and NS% were positively correlated at T2 and T3 while anti-RBD IgG value predicting a NS% > 60 markedly differed at T2 and T3 (594 vs. 108 BAU/mL, respectively). While a high neutralizing bioactivity was maintained at least 6 months after vaccination in almost all individuals, the mean values of anti-RBD-IgG showed a marked decline at 6 months. The absolute value of anti-RBD IgG is a poor marker of neutralizing bioactivity.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Long-term kinetics of anti-RBD IgG and neutralizing antibodies were analyzed in a cohort of COVID-19 naïve health care workers (HCW) undergoing SARS-CoV-2 vaccination.
METHODS
METHODS
An anti-RBD IgG immunoassay and a surrogate virus neutralization test (sVNT) were performed at different time points up to 6 months after vaccination in 57 HCWs. Values of anti-RBD IgG predicting an high neutralizing bioactivity (>60%) were also calculated.
RESULTS
RESULTS
Mean (range) values of anti-RBD IgG were 294.7 (11.6-1554), 2583 (398-8391), 320.4 (42.3-1134) BAU/mL at T1 (21 days after the 1st dose [T0]), T2 (30 days after the 2nd dose) and T3 (+180 days after T0), respectively. Mean (range) percentages of neutralization (NS%) were 24 (0-76), 86 (59-96) and 82 (52-99) at T1, T2 and T3, respectively. Anti-RBD IgG values and NS% were positively correlated at T2 and T3 while anti-RBD IgG value predicting a NS% > 60 markedly differed at T2 and T3 (594 vs. 108 BAU/mL, respectively).
CONCLUSION
CONCLUSIONS
While a high neutralizing bioactivity was maintained at least 6 months after vaccination in almost all individuals, the mean values of anti-RBD-IgG showed a marked decline at 6 months. The absolute value of anti-RBD IgG is a poor marker of neutralizing bioactivity.
Identifiants
pubmed: 34843705
pii: S0009-8981(21)00413-7
doi: 10.1016/j.cca.2021.11.023
pmc: PMC8630423
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-17Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Open Forum Infect Dis. 2021 Apr 30;8(6):ofab220
pubmed: 34136587
J Med Virol. 2021 Jan;93(1):311-322
pubmed: 32633840
Infection. 2021 Feb;49(1):75-82
pubmed: 32827125
J Infect. 2021 Oct;83(4):e4-e5
pubmed: 34407421
Microorganisms. 2020 Oct 13;8(10):
pubmed: 33066057
Viruses. 2021 Sep 30;13(10):
pubmed: 34696403
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Lancet Respir Med. 2021 Nov;9(11):1255-1265
pubmed: 34391547
Viruses. 2021 Jul 14;13(7):
pubmed: 34372570
Vaccine. 2021 Sep 24;39(40):5963-5967
pubmed: 34400017
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Vaccines (Basel). 2021 Sep 28;9(10):
pubmed: 34696200
Clin Transl Immunology. 2021 Feb 28;10(3):e1258
pubmed: 33680466
J Infect Dis. 2021 Sep 1;224(5):764-770
pubmed: 34086960
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
Int J Infect Dis. 2021 May;106:61-64
pubmed: 33713819
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Lancet Microbe. 2021 Jun;2(6):e240-e249
pubmed: 33778792
PLoS Negl Trop Dis. 2021 Jul 8;15(7):e0009551
pubmed: 34237072
Cell Mol Immunol. 2021 Sep;18(9):2128-2139
pubmed: 34290398
Int J Mol Sci. 2021 Mar 08;22(5):
pubmed: 33800363
Clin Infect Dis. 2021 Nov 2;73(9):e3095-e3097
pubmed: 32927483
J Virol Methods. 2021 Jun;292:114122
pubmed: 33705832
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33974565
J Clin Med. 2021 May 14;10(10):
pubmed: 34069088
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
Am J Hematol. 2021 Jul 1;96(7):E257-E259
pubmed: 33837984
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Nat Rev Immunol. 2021 Jun;21(6):395-404
pubmed: 33927374
J Infect Dis. 2020 Nov 13;222(12):1974-1984
pubmed: 32910175
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
Nature. 2021 Jul;595(7867):359-360
pubmed: 34127832
Lancet Microbe. 2022 Jul;3(7):e493-e502
pubmed: 35636436
Nat Med. 2021 Jul;27(7):1147-1148
pubmed: 34239135
BMC Med. 2021 Aug 23;19(1):208
pubmed: 34420521
Clin Infect Dis. 2021 Dec 16;73(12):2155-2162
pubmed: 33624751
Immunity. 2020 Dec 15;53(6):1272-1280.e5
pubmed: 33242394
Nat Commun. 2020 Aug 13;11(1):4059
pubmed: 32792628
Lancet. 2021 Apr 10;397(10282):1347-1348
pubmed: 33770519
J Occup Environ Med. 2021 Nov 1;63(11):e829
pubmed: 34412098
Vaccines (Basel). 2021 Jun 25;9(7):
pubmed: 34202276
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Front Immunol. 2020 Sep 17;11:570018
pubmed: 33042151
Immunity. 2021 Aug 10;54(8):1841-1852.e4
pubmed: 34246326
Sci Transl Med. 2021 Jun 30;13(600):
pubmed: 34103407
Cells. 2021 Jul 30;10(8):
pubmed: 34440710
Sci Rep. 2021 Sep 3;11(1):17642
pubmed: 34480056
Vaccines (Basel). 2021 Jun 18;9(6):
pubmed: 34207300
Microbiol Spectr. 2021 Oct 31;9(2):e0059021
pubmed: 34550000
Nat Commun. 2021 Feb 8;12(1):844
pubmed: 33558507
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Emerg Microbes Infect. 2020 Dec;9(1):2394-2403
pubmed: 33043818
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
N Engl J Med. 2021 May 6;384(18):1774-1775
pubmed: 33755376
Signal Transduct Target Ther. 2021 Feb 26;6(1):95
pubmed: 33637679
J Clin Microbiol. 2021 Aug 18;59(9):e0098921
pubmed: 34165323
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):632-638
pubmed: 33914721
J Med Virol. 2021 Dec;93(12):6765-6777
pubmed: 34387884
EBioMedicine. 2021 Sep;71:103544
pubmed: 34419925